Inotiv (NASDAQ:NOTV) and NLS Pharmaceutics (NASDAQ:NCEL) Head-To-Head Contrast

NLS Pharmaceutics (NASDAQ:NCEL) and Inotiv (NASDAQ:NOTV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Institutional & Insider Ownership

18.2% of Inotiv shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 7.8% of Inotiv shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares NLS Pharmaceutics and Inotiv”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30 million	N/A	N/A
Inotiv	$507.36 million	0.00	-$68.62 million	($2.53)	-0.01

NLS Pharmaceutics has higher earnings, but lower revenue than Inotiv.

Analyst Ratings

This is a breakdown of current ratings for NLS Pharmaceutics and Inotiv, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1	0	1	0	2.00
Inotiv	1	0	1	0	2.00

NLS Pharmaceutics currently has a consensus price target of $23.00, suggesting a potential upside of 489.74%. Inotiv has a consensus price target of $1.50, suggesting a potential upside of 8,326.97%. Given Inotiv’s higher possible upside, analysts clearly believe Inotiv is more favorable than NLS Pharmaceutics.

Profitability

This table compares NLS Pharmaceutics and Inotiv’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Inotiv	-17.14%	-56.77%	-8.91%

Risk & Volatility

NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Inotiv has a beta of 3.77, suggesting that its stock price is 277% more volatile than the S&P 500.

Summary

NLS Pharmaceutics beats Inotiv on 5 of the 9 factors compared between the two stocks.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.